ATRA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Allogeneic T-cell PlatformAtara’s focus on allogeneic, off-the-shelf T-cell therapies gives it a defined technology platform spanning EBV-associated cancers, tumor-associated targets, and engineered CAR T programs. A platform approach can support multiple clinical opportunities from related capabilities over the medium term.
High Gross MarginThe company retains high gross margin in the TTM period despite its broader deterioration. If maintained as programs advance, that margin profile could provide attractive economics on successful collaboration or commercialization, although current results do not yet demonstrate durable earnings.
Partnership-based Funding ModelCollaboration and license arrangements provide a route to funding and future economics beyond direct product sales, including upfront payments, milestones, and royalties. Existing arrangements with large pharmaceutical companies can extend development or commercialization reach, though payments remain contingent.
Bears Say
Severe Revenue DeteriorationThe sharp TTM revenue contraction and return to a sizable loss indicate that recent earnings power is highly unstable. This weakens internal funding capacity and makes progress more dependent on successful clinical development, partnering activity, or future financing.
Negative Equity And Leverage RiskPersistently negative shareholders’ equity, combined with debt and ongoing losses, signals limited financial flexibility. The balance-sheet position can constrain investment in development programs and heighten reliance on external capital, increasing exposure to funding and dilution risk.
Persistent Cash BurnNegative operating and free cash flow across the reported periods shows that the business is not currently self-funding its operations. Continued cash burn can force additional financing before products generate recurring revenue, raising execution pressure and potential shareholder dilution.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is CHF78.35M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 14 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Aug 12, 2026. The company reported -CHF0.266 earnings per share for the quarter, missing the consensus estimate of -CHF0.262 by -CHF0.004.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -0.11.
How many shares outstanding does Atara Biotherapeutics have?
Currently, no data Available
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -CHF0.266 in its last earnings report, missing expectations of -CHF0.262. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Currently, no hedge funds are holding shares in CH:ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF12.90 (― Upside)
CHF12.90 (― Upside)
Blogger Sentiment
Neutral
CH:ATRA Sentiment 50%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth CHF799.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.13%
12-Months-Change
Fundamentals
Return on Equity
44.67%
Trailing 12-Months
Asset Growth
-43.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.